{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-076633","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.428050+00:00","generated_at":"2026-05-17T13:46:21.840677+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuCell swings to Q2 profit of $502k on 18% sales growth to $6.4M","bullets":["Q2 product sales $6.4M, up 18% YoY; H1 sales $14.5M, up 14%.","Net income $502k ($0.06/diluted) vs loss of ($1.5M) in Q2 2024.","Gross margin improved to 44% from 22%; adjusted EBITDA $1.4M in Q2.","Cash rose to $6.0M from $3.8M at Dec 2024; no line-of-credit draws.","Re-Tain: initiating field feedback, reducing R&D spend, exploring strategic options."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-076633","json":"https://secwatch.observer/filing/0001213900-25-076633.json","markdown":"https://secwatch.observer/filing/0001213900-25-076633.md","text":"https://secwatch.observer/filing/0001213900-25-076633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390025076633/0001213900-25-076633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390025076633/ea0253265-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:46:21.840677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}